Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 1
1991 2
1992 4
1993 4
1995 5
1996 4
1997 2
1998 1
2003 3
2004 3
2005 3
2006 8
2007 2
2008 6
2009 1
2010 4
2011 3
2012 5
2013 3
2014 10
2015 8
2016 12
2017 4
2018 7
2019 6
2020 6
2021 6
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Wolf's isotopic response of lichen planus following contact dermatitis.
Pollard B, McCoy WH 4th, Leonardi CL, Martin AG. Pollard B, et al. Among authors: leonardi cl. JAAD Case Rep. 2022 Jul 16;27:128-130. doi: 10.1016/j.jdcr.2022.07.010. eCollection 2022 Sep. JAAD Case Rep. 2022. PMID: 36046802 Free PMC article. No abstract available.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN. Fernandez AP, et al. Among authors: leonardi cl. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774-1783. doi: 10.1111/jdv.18167. Epub 2022 Jun 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35460287 Free PMC article. Clinical Trial.
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.
Bissonnette R, Gottlieb AB, Langley RG, Leonardi CL, Papp KA, Pariser DM, Uy J, Lafferty KP, Langholff W, Fakharzadeh S, Berlin JA, Brouwer ES, Greenspan AJ, Strober BE. Bissonnette R, et al. Among authors: leonardi cl. Drug Saf. 2021 Jun;44(6):699-709. doi: 10.1007/s40264-021-01065-z. Epub 2021 Jun 2. Drug Saf. 2021. PMID: 34075572 Free PMC article. Review.
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Blauvelt A, Leonardi CL, Gaylis N, Jauch-Lembach J, Balfour A, Lemke L, Hachaichi S, Brueckmann I, Festini T, Wiland P. Blauvelt A, et al. Among authors: leonardi cl. BioDrugs. 2021 Mar;35(2):229-238. doi: 10.1007/s40259-021-00470-1. Epub 2021 Mar 2. BioDrugs. 2021. PMID: 33651341 Free PMC article. Clinical Trial.
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
Mrowietz U, Warren RB, Leonardi CL, Saure D, Petto H, Hartz S, Dossenbach M, Reich K. Mrowietz U, et al. Among authors: leonardi cl. J Eur Acad Dermatol Venereol. 2021 May;35(5):1161-1175. doi: 10.1111/jdv.17130. Epub 2021 Feb 15. J Eur Acad Dermatol Venereol. 2021. PMID: 33480102 Free PMC article.
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter MA. Lebwohl MG, et al. Among authors: leonardi cl. J Am Acad Dermatol. 2021 Feb;84(2):398-407. doi: 10.1016/j.jaad.2020.09.047. Epub 2020 Sep 19. J Am Acad Dermatol. 2021. PMID: 32961255 Free article. Clinical Trial.
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Elmets CA, et al. Among authors: leonardi cl. J Am Acad Dermatol. 2021 Feb;84(2):432-470. doi: 10.1016/j.jaad.2020.07.087. Epub 2020 Jul 30. J Am Acad Dermatol. 2021. PMID: 32738429
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Blauvelt A, et al. Among authors: leonardi cl. JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723. JAMA Dermatol. 2020. PMID: 32267471 Free PMC article. Clinical Trial.
117 results